Visual hallucinations as REM sleep behavior disorders in patients with Parkinson's disease

Movement Disorders

Volumn 18, Issue 7, 2003, Pages 812-817

  Nomura, Takashi ^a   Inoue, Yuichi ^b   Mitani, Hidetaka ^a   Kawahara, Ryuzo ^a   Miyake, Masahiro ^a   Nakashima, Kenji ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

Author keywords

Clonazepam; Hallucination; Parkinson's disease; Polysomnography; REM sleep disorder

Indexed keywords

AMANTADINE; BROMOCRIPTINE; CABERGOLINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PERGOLIDE; TALIPEXOLE; TRIHEXYPHENIDYL;

AGED; ARTICLE; ATAXIA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DREAM; DRUG CHOICE; DRUG EFFICACY; ELECTROMYOGRAPHY; FEMALE; HUMAN; LATENT PERIOD; MALE; PARASOMNIA; PARKINSON DISEASE; PATHOPHYSIOLOGY; POLYSOMNOGRAPHY; PRIORITY JOURNAL; REM SLEEP; SLEEP STAGE; SOMNOLENCE; STANDARDIZATION; VISUAL HALLUCINATION;

AGED; ANTICONVULSANTS; ANTIPARKINSON AGENTS; CEREBRAL CORTEX; CIRCADIAN RHYTHM; CLINICAL TRIALS; CLONAZEPAM; DOSE-RESPONSE RELATIONSHIP, DRUG; DREAMS; DRUG THERAPY, COMBINATION; FEMALE; HALLUCINATIONS; HUMANS; MALE; PARKINSON DISEASE; POLYSOMNOGRAPHY; REACTION TIME; REM SLEEP BEHAVIOR DISORDER; SLEEP, REM; TREATMENT OUTCOME;

EID: 0041589674     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10439     Document Type: Article

References (28)

1. Tanner CM, Vogel C, Goetz CG, Klawans HL. Hallucinations in Parkinson's disease: a population study [abstract]. Ann Neurol 1983;14:136.
2. Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995;45:669-671.
3. Cummings JL. Behavior complication of drug treatment of Parkinson's disease. J Am Geriatr Soc 1991;39:708-716.
4. Schenck CH, Bundlie SR, Ettinger MG, Mahowald MW. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep 1986;9:293-308.
5. Schenck CH, Bundlie SR, Patterson AL, Mahowald MW. Rapid eye movement sleep behavior disorder: a treatable parasomnia affecting older adults. JAMA 1987;257:1786-1789.
6. ICSD International Classification of Sleep Disorders: diagnosis and coding manual. Diagnostic classification steering committee. Rochester, MN: American Sleep Disorders Association; 1990.
7. Sharf B, Moskovitz C, Lupton MD, Klawans HL. Dream phenomena induced by chronic levodopa therapy. J Neural Transm 1978; 43:143-151.
8. Chokroverty S. Diagnosis and treatment of sleep-disorders caused by comorbid disease. Neurology 2000;54(Suppl. 1):S8-S15.
9. Carskadon MA, Dement WC, Milter MM, et al. Guideline for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep 1986;9:519-524.
10. Hasegawa K. The new Parkinson's disease drugs. Nippon Rinsho 2000;58:2066-2071.
11. Arnulf I, Konofal E, Merino-Andreu M, et al. Parkinson's disease and sleepiness. An integral part of PD. Neurology 2002;58:1019-1024.
12. Rechtschaffen A, Kales AA. A manual of standardized terminology, techniques and scoring system for sleep stages in human subjects. Washington, DC: US Government Printing Office, Public Health Service; 1968.
13. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1984;14:540-545.
14. Tachibana M, et al. A sleep study of acute psychotic states due to alcohol and meprobamate addiction. In: Weitzman ED, editor. Advances in sleep research. New York: Spectrum; 1975. p 177-205.
15. Aldrich MS, Chervin RD, Malow BA. Value of the multiple sleep latency test (MSLT) for the diagnosis of narcolepsy. Sleep 1997; 20:620-629.
16. McKeith IG, Galasko D, Kosaka K, et al. Consensus guideline for the clinical and pathologic diagnosis of dementia with Lewy Bodies (DLBD): report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124.
17. Aarsland D, Larson JP, Cummins JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-base study. Arch Neurol 1999;56:595-601.
18. Comell CL, Nardine TM, Diederich NJ, Stebbins GT. Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson's disease. Neurology 1998;51:526-529.
19. Arnulf I, Bonnet AM, Damier P, Bejjani BP, Seihean D, Derenne JP, Agid Y. Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology 2000;55:281-288.
20. Rye DB, Johnston LH, Watts RL, Bliwise DL. Juvenile Parkinson's disease with REM sleep behavior disorder, sleepiness, and daytime REM onset. Neurology 1999;53:1868-1870.
21. Guilleminaut C, Anagnos A. Narcolepsy. In: Kryger MN, Roth T, editors. Principles and practice of sleep medicine. 3rd ed. Philadelphia: WB Saunders; 2000. p 676-686.
22. Larsen JP, Tandberg E. Sleep disorders in patients with Parkinson's disease: epidemiology and management. CNS Drug 2001; 15:267-275.
23. Aldrich MS. Narcolepsy. Neurology 1992;42(Suppl. 6):34-43.
24. Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 1997;52:27-78.
25. Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 elder men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder. Neurology 1996;46:388-393.
26. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2000;55:789-794.
27. Mahowald HW, Schenck CH. REM sleep behavior disorders In: Kryger MN, Roth T, editors. Principles and practice of sleep medicine. 2nd ed. Philadelphia: WB Saunders; 1994. p 574-578.
28. Schenck CH, Mahowald MW. Polysomnographic, neurologic, psychiatric, and clinical outcome report on 70 consecutive cases with the REM sleep behavior disorders (RBD): sustained clonazepam efficacy in 89.5% of 57 treated patients. Clev Clin J Med 1990; 57:9-23.